HER2 ICD peptide vaccine

HER2 ICD peptide vaccine is an investigational **multipeptide therapeutic cancer vaccine** developed at the University of Washington Cancer Vaccine Institute. It contains three synthetic helper-T-cell epitopes from the intracellular domain of human epidermal growth factor receptor 2: p776-790, p927-941, and p1166-1180, administered with granulocyte-macrophage colony-stimulating factor as an immune adjuvant. The vaccine is intended to prime and expand HER2-specific cellular immunity against HER2-overexpressing tumors, particularly breast cancer. It has been evaluated in University of Washington-led Phase I and Phase I/II clinical studies, including a randomized study in stage IV HER2-positive breast cancer given alongside standard HER2-targeted monoclonal-antibody therapy. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10754340/))

Other names

HER-2/neu intracellular domain peptide-based vaccineHER2 multi-peptide vaccineHER-2 multi-peptide vaccineHER 2 multi-peptide vaccineHER2 ICD peptide-based vaccineHER-2 ICD peptide-based vaccineHER 2 ICD peptide-based vaccine